<SEC-DOCUMENT>0001178913-21-003161.txt : 20211013
<SEC-HEADER>0001178913-21-003161.hdr.sgml : 20211013
<ACCEPTANCE-DATETIME>20211013083741
ACCESSION NUMBER:		0001178913-21-003161
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211013
FILED AS OF DATE:		20211013
DATE AS OF CHANGE:		20211013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		211320221

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2126646.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">FORM 6-K</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of October 2021</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; line-height: 1.25;">_______________________</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
        <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; line-height: 1.25;">_______________________</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street<br>
          Modi&#8217;in 7177871, Israel</div>
        <div style="text-align: center; line-height: 1.25;">&#160;(Address of Principal Executive Offices)</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; line-height: 1.25;">_______________________</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: &#160; &#160; &#160; &#160;</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F &#9746;&#160; &#160; &#160; &#160; &#160; Form 40-F &#9744;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</div>
      <br>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="text-align: justify; line-height: 1.25;">On October 13, 2021 the registrant issued the press release which is filed as <a href="exhibit_1.htm"><u>Exhibit
              1</u></a> to this Report on Form 6-K.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">The first two paragraphs of the press release attached to this Form 6-K are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd3431d8e66c43f9b947ca90af924db9">

          <tr>
            <td style="width: 49.97%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="2" style="width: 27.05%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
            </td>
            <td style="width: 22.98%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td style="width: 23.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
            </td>
            <td style="width: 22.98%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 23.96%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">Philip A. Serlin</div>
            </td>
            <td style="width: 22.98%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.97%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 23.96%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 22.98%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;">Dated: October 13, 2021</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>BIOLINERX ANNOUNCES POSITIVE RESULTS FROM PHARMACOECONOMIC STUDY POSITIONING MOTIXAFORTIDE AS POTENTIAL STANDARD OF CARE IN STEM CELL MOBILIZATION
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br>
    </div>
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><img width="285" height="38" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Announces Positive Results from </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Pharmacoeconomic Study Positioning Motixafortide as </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Potential Standard of Care in Stem Cell Mobilization</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- Results demonstrate significant cost benefits of using Motixafortide in combination </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">with G-CSF as standard-of-care mobilization therapy for all multiple myeloma patients </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">undergoing autologous stem cell transplantation -</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">- Results from pre-planned study, on top of highly significant and clinically meaningful </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">results from Phase 3 GENESIS trial announced in May 2021, strongly support potential </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">use of Motixafortide as standard of care in stem cell mobilization -</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Tel Aviv, Israel, October 13, 2021 &#8211; BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a
        pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma
        patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, and was a pre-planned study conducted in parallel with the GENESIS Phase 3 trial.
        These results, together with the highly significant and clinically meaningful data from the GENESIS trial, strongly support the potential use of Motixafortide, on top of G-CSF, as the standard of care in SCM for ASCT.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The study concluded that the addition of Motixafortide to G-CSF (the current standard of care) is associated with a statistically significant decrease in health resource utilization (HRU) during
        the ASCT process, compared to G-CSF alone. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime estimates show quality-adjusted-life-year (QALY) benefits and net cost savings of ~$17,000
        (not including the cost of Motixafortide), versus G-CSF alone. The study findings, combined with model estimates, suggest that the use of Motixafortide, on top of G-CSF, as the standard of care in mobilization for ASCT, could be a cost-effective
        option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;The compelling cost savings identified by this rigorously designed study strongly support the Company&#8217;s view that Motixafortide, in combination with G-CSF, can become the new standard of care as
        an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation,&#8221; stated Philip Serlin, Chief Executive Officer of BioLineRx. &#8220;Based on data from the GENESIS trial showing that nearly 90% of
        patients collected an optimal number of cells for transplantation following a single administration of Motixafortide and in only one apheresis session, versus less than 10% for G-CSF alone, the pharmacoeconomic study demonstrates that use of
        Motixafortide on top of G-CSF can save $17,000 per patient, not including the cost of Motixafortide. These cost savings should leave substantial room in the future to optimize our pricing strategy for Motixafortide at product launch and thereafter,
        if approved.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;It is also important to note that fewer administrations and apheresis sessions confer meaningful safety and time benefits to patients. In addition, the significantly higher median number of cells
        collected in one apheresis session &#8211; ~11 million using Motixafortide on top of G-CSF versus ~2 million for G-CSF alone &#8211; not only enables transplantation of an optimal number of cells, with the potential to significantly save on time to
        engraftment, it also permits the retention of enough cells for cryopreservation in the event that an additional transplantation is required in the future. Lastly, higher levels of certainty regarding the number of apheresis sessions required for
        mobilization could enable more efficient utilization of apheresis units at transplantation institutions, where there is often a shortage of available machines.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;We believe the data from the GENESIS study, together with the results from this pharmacoeconomic study, set Motixafortide apart from all other mobilization agents either currently available or in
        development. If approved, Motixafortide represents a significant advancement in SCM to the benefit of patients and payers alike, and, to that end, we remain on track to submit a New Drug Application (NDA) to the FDA in the first half of next year,&#8221;
        Mr. Serlin concluded.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About the Pharmacoeconomic Study</div>
      <div style="text-align: justify; line-height: 1.25;">The pharmacoeconomic study analyzed healthcare resource utilization (HRU) observed during the Phase 3 GENESIS trial, which randomized 122 patients into two arms: Motixafortide plus G-CSF (n=80) or
        placebo plus G-CSF (n=42). HRU data points collected include: (1) the number of Motixafortide and G-CSF doses, as well as the number of apheresis sessions performed, in primary mobilization; (2) the percentage of patients needing rescue
        mobilization due to poor primary mobilization, including the number of apheresis sessions needed and the number of G-CSF and plerixafor doses required; and (3) hospitalization costs related to conditioning and transplantation, including length of
        stay. Quality-adjusted life years gained (QALY) from published literature were also incorporated into the model. Motixafortide plus G-CSF was associated with a statistically significant HRU decrease during the autologous stem cell transplantation
        process compared to standard-of-care G-CSF alone. Given the higher number of mobilized cells and lower number of apheresis sessions, lifetime estimates show quality-adjusted-life-year (QALY) benefits and net cost savings of ~$17,000 (not including
        the cost of Motixafortide), versus the current standard of care.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About the GENESIS Phase 3 Trial</div>
      <div style="text-align: justify; line-height: 1.25;">The GENESIS Phase 3 trial (NCT03246529) was initiated in December 2017. GENESIS was a randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of
        Motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients. The primary objective of the study was to demonstrate that only one dose of
        Motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize &#8805; 6 million CD34+ cells in up to two apheresis sessions. Additional objectives included time to engraftment of neutrophils and platelets and durability of
        engraftment, as well as other efficacy and safety parameters. The study successfully met all primary and secondary endpoints with an exceptionally high level of statistical significance (p&lt;0.0001), including approximately 90% of patients who
        mobilized the target number of cells for transplantation with only one administration of Motixafortide and in only one apheresis session.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Stem Cell Mobilization for Autologous Stem Cell Transplantation</div>
      <div style="text-align: justify; line-height: 1.25;">Autologous stem cell transplantation (ASCT) is part of the standard treatment paradigm for a number of blood cancers, including multiple myeloma, non-Hodgkin&#8217;s lymphoma and other lymphomas. In
        eligible patients, ASCT is performed after initial (induction) therapy, and, in most cases, requires consecutive-day clinic visits for the mobilization and apheresis (harvesting) phases, and full hospitalization for the conditioning chemotherapy
        and transplantation phases until engraftment. The associated burden is therefore significant &#8211; patients experience clinically relevant deteriorations in their quality of life during ASCT, and healthcare resource use throughout the ASCT phases is
        particularly intense. Therefore, new interventions impacting the ASCT process have the potential for relieving some of the clinical burden for transplanted patients, the logistical burden for the apheresis units, and the financial burden for
        healthcare providers and payers.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Described simply, ASCT consists of: (1) mobilizing the patient&#8217;s own stem cells from his/ her bone marrow to the peripheral blood for removing (harvesting) via an apheresis procedure; (2) freezing
        and storing the harvested cells until they are needed for transplantation; (3) providing a conditioning treatment, such as high-dose chemotherapy or radiation, to kill the remaining cancer cells the day before transplant; and (4) infusing the
        stored stem cells back to the patient intravenously via a catheter.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">To mobilize the patient&#8217;s stem cells from the bone marrow to the peripheral blood for harvesting, the current standard of care includes the administration of 5-8 daily doses of granulocyte colony
        stimulating factor (G-CSF), and the performance of 1-4 apheresis sessions. For patients unable to mobilize sufficient numbers of cells for harvesting during this primary mobilization phase, rescue therapy is carried out, consisting of 1-4 doses of
        plerixafor on top of G-CSF, and the performance of an additional number of apheresis sessions as necessary. In light of this, an agent with superior mobilization activity may significantly reduce the mobilization and harvesting burden and
        associated risks of the ASCT process and lead to significant clinical and resource benefits.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
      <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company&#8217;s business model is to in-license novel compounds, develop them through
        clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow
        transplantation, as well as reporting positive results from a pre-planned pharmacoeconomic study, and is currently in preparations for an NDA submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of
        pancreatic cancer in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        and chemotherapy as a first-line PDAC therapy.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">For additional information on BioLineRx, please visit the Company&#8217;s website at <u>www.biolinerx.com</u>, where you can review the Company&#8217;s SEC filings, press releases, announcements and events.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation
        Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties
        that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause
        BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and
        other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; BioLineRx's receipt of regulatory approvals for
        its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates; BioLineRx's ability to establish and maintain corporate
        collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic
        candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for
        intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its
        needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; risks related to the COVID-19 pandemic; and
        statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with
        the Securities and Exchange Commission on February 23, 2021. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent
        date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
        <div style="text-align: justify; line-height: 1.25;">Tim McCarthy</div>
        <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
        <div style="text-align: justify; line-height: 1.25;">+1-212-915-2564</div>
        <div style="text-align: justify; line-height: 1.25;"><u>tim@lifesciadvisors.com</u></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">or</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
        <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
        <div style="text-align: justify; line-height: 1.25;">+972-54-476-4945</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
      <div id="DSPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 HP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R/%&J3Z)X5U35+9(WGM+9YD60$J2
M!D9P0<?C6O7-_$'_ ))YX@_Z\9?_ $$U4=9(3V/'_P#A>WBC_GPTC_OS+_\
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M_';_ )$>S_[",?\ Z+DKY[KZ$^.W_(CV?_81C_\ 1<E?/=/!_P (,7\9[!\
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MC_%1],4445XAZH4444 %%%% !1110!XO\??]7HO^_)_(5XI7M?Q]_P!7HO\
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MY1^(?_)1=?\ ^OH_^@K7U=7RC\0_^2BZ_P#]?1_]!6G@?C?H&+_AF!9_\?\
M:_\ 7=/_ $(5]ER$K&S#J 37QI9_\?\ :_\ 7=/_ $(5]E3?ZF3_ '358[>)
M.#^%GQSJ;%M7OF/5KF4G_OLUN_#W^S/^$VL?[9^Q_8,/YGVS;Y73C.[BL#4?
M^0I>_P#7Q)_Z$:KUW./-"QQ\W+4N?3W_ !;#_J4/_):C_BV'_4H?^2U?,-%<
MWU3^\S?ZU_=1]/?\6P_ZE#_R6H_XMA_U*'_DM7S#11]4_O,/K7]U'T]_Q;#_
M *E#_P EJ4#X8D@ >$"2< ?Z-7S!3X/^/F'_ *Z+_,4/"?WF-8F[MRH^MO\
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M[:=8T\A"HP5SSDFHJ8:<(\TBX5X3=D<I\??]7HO^_)_(5XI7M?Q]_P!7HO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
